Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase I Study of Ex Vivo Liver-Directed Gene Therapy for Familial Hypercholesterolemia
This study has been completed.
First Received: February 24, 2000   Last Updated: June 23, 2005   History of Changes
Sponsors and Collaborators: National Center for Research Resources (NCRR)
University of Pennsylvania
Information provided by: Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier: NCT00004809
  Purpose

OBJECTIVES:

I. Develop an approach for treating patients with homozygous familial hypercholesterolemia using gene therapy with autologous hepatocytes transduced with a normal low-density lipoprotein receptor gene.


Condition Intervention Phase
Familial Hypercholesterolemia
Procedure: gene therapy
Phase I

Study Type: Interventional
Study Design: Treatment

Resource links provided by NLM:


Further study details as provided by Office of Rare Diseases (ORD):

Estimated Enrollment: 5
Study Start Date: June 1992
Detailed Description:

PROTOCOL OUTLINE: Autologous hepatocytes are obtained from a partial hepatectomy and transduced with a recombinant retroviral vector containing the low-density lipoprotein receptor gene. The transduced hepatocytes are infused via the inferior mesenteric vein 3 days following surgery.

Traditional therapy is discontinued for 4 weeks prior to protocol therapy and may resume 6 weeks after the hepatocyte infusion.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Homozygous familial hypercholesterolemia, i.e.: Low-density lipoprotein (LDL) cholesterol greater than 500 mg/dL Autosomal dominant inheritance Early-onset tendon and tuberous xanthomas LDL receptor negative, i.e.: Receptor binding in cultured fibroblasts no more than 20% of normal OR Genotype with 2 previously described, disease-causing alleles Advanced coronary heart disease with relatively poor prognosis, i.e: Angina pectoris History of myocardial infarction Positive exercise tolerance test Atherosclerotic disease in proximal aorta or coronary arteries by ultrasound or angiogram None of the following: Unstable angina pectoris Left ventricular ejection fraction less than 30% Decompensated congestive heart failure Untreated ventricular tachycardia Moderate to severe aortic stenosis Other dyslipidemia Obstructive hepatobiliary disease

  • Prior/Concurrent Therapy At least 2 weeks since the following: Drugs affecting cholesterol metabolism Plasma exchange LDL apheresis --Patient Characteristics-- Age: Any age Renal: No azotemia No significant proteinuria Other: No hypothyroidism No diabetes
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004809

Sponsors and Collaborators
University of Pennsylvania
Investigators
Study Chair: James M. Wilson University of Pennsylvania
  More Information

No publications provided

Study ID Numbers: 199/12011, UPHS-28040
Study First Received: February 24, 2000
Last Updated: June 23, 2005
ClinicalTrials.gov Identifier: NCT00004809     History of Changes
Health Authority: United States: Federal Government

Keywords provided by Office of Rare Diseases (ORD):
familial hypercholesterolemia
inborn errors of metabolism
rare disease

Study placed in the following topic categories:
Lipid Metabolism, Inborn Errors
Hyperlipidemias
Metabolic Diseases
Hyperlipoproteinemia Type II
Rare Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Hypercholesterolemia, Autosomal Dominant
Hypercholesterolemia
Metabolic Disorder
Hyperlipoproteinemias
Dyslipidemias
Lipid Metabolism Disorders

Additional relevant MeSH terms:
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Metabolic Diseases
Hyperlipidemias
Genetic Diseases, Inborn
Hyperlipoproteinemia Type II
Hypercholesterolemia
Hyperlipoproteinemias
Dyslipidemias
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on July 02, 2009